FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with pharmaceutical composition, containing suspension, which includes mixture of hydrophobic medium and solid form, where solid form contains therapeutically effective quantity of octreotide and, at least, one salt of fatty acid with medium chain length, which has chain length from 6 to 14 carbon atoms, and matrix-forming polymer, selected from dextran and polyvinylpyrrolidone (PVP), with salt of fatty acid with medium chain length being present in composition in amount of 10% by weight or more. Group of inventions also deals with capsule, containing said composition, intended for peroral introduction; method of obtaining said pharmaceutical composition.
EFFECT: group of inventions relates to improvement of octreotide bioavailability.
100 cl, 39 ex, 10 dwg, 45 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS AND RELATED DELIVERY METHODS | 2009 |
|
RU2678833C2 |
| PERORAL COMPOSITIONS CONTAINING ESTER 17- HYDROXYPROHESTERON, AND CORRESPONDING METHODS | 2012 |
|
RU2640912C2 |
| VELDORETID, HAVING POOR SOLUBILITY IN PHYSIOLOGICAL CONDITIONS, FOR USE IN TREATING ACROMEGALY, ACROMEGALY WITH MALIGNANT GROWTH, EXPRESSING SST-R5 TUMORS, TYPE 2 DIABETES, HYPERGLYCEMIA AND TUMORS ASSOCIATED WITH HORMONES | 2017 |
|
RU2736590C2 |
| DOSING MODES FOR ECHINOCANDINE CLASS COMPOUNDS | 2013 |
|
RU2639483C2 |
| DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | 2013 |
|
RU2719579C2 |
| ADVANCED DRUG DELIVERY SYSTEM | 2004 |
|
RU2353350C2 |
| OPHTHALMIC COMPOSITION | 2012 |
|
RU2639472C2 |
| METHODS AND COMPOSITIONS FOR PREVENTING OR MINIMIZING EPITHELIAL-MESENCHYMAL TRANSITION | 2017 |
|
RU2764630C2 |
| OCTREOTIDE DELIVERY FROM DRY DOSAGE FORMS | 2009 |
|
RU2518745C2 |
| OCTREOTIDE IMPLANT CONTAINING RELEASING SUBSTANCE | 2009 |
|
RU2521291C2 |
